Seven of twelve with body dysmorphia responded to one dose
What they did
Twelve adults with moderate to severe body dysmorphic disorder that had not responded to at least one antidepressant received a single 25mg dose of psilocybin with psychological support, then were followed for twelve weeks.
What they found
Severity scores fell significantly over twelve weeks and seven of twelve participants, or 58 percent, met the responder threshold. No serious adverse events occurred.
Worth knowing
Open-label with no control group, so expectancy is unmeasured. Twelve people in a condition where symptom severity naturally fluctuates.
Schneier et al. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. Journal of Psychiatric Research, 2023.
Read the sourceKeep reading
eating disordersTwenty-one women with anorexia, and symptoms that improved for a yearOCDOne small trial is the entire case for psilocybin and OCDcluster headacheCluster headaches dropped on psilocybin, but not significantlyWe include the trials that missed their endpoints alongside the ones that hit. A shelf that only holds good news is a marketing page, not a library.
For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.